Fabry disease, enzyme replacement therapy and the significance of antibody responses (Q37950838)

25 August 2017

Fabry disease, enzyme replacement therapy and the significance of antibody responses (English)

1 reference

enzyme replacement therapy

25 August 2017

0 references

1 reference

1 reference

Patrick B Deegan

1

1 reference

25 August 2017

25 October 2011

1 reference

Journal of Inherited Metabolic Disease

25 August 2017

1 reference

25 August 2017

35

1 reference

25 August 2017

227-243

1 reference

25 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-011-9400-y

25 August 2017

0 references

cites work

A CASE OF “ANGEIO-KERATOMA.”

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Carbohydrate-Specific Receptors of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Efficacy of enzyme replacement therapy in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Pathophysiology of protein and vitamin handling in the proximal tubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Successful oral tolerance induction in severe peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Quality of life of patients with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Why are some proteins allergens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Getting the glycosylation right: implications for the biotechnology industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Agalsidase Beta: a review of its use in the management of Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

The heart in Anderson-Fabry disease and other lysosomal storage disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Screening for Fabry disease in high-risk populations: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Inhibitor antibodies to factor VIII and factor IX: management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Prevalence of lysosomal storage diseases in Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

The frequency of lysosomal storage diseases in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Human immune response to recombinant human proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Immunogenicity of therapeutic proteins: clinical implications and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Immunogenicity of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Factors influencing the immunogenicity of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

High incidence of later-onset fabry disease revealed by newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9400-Y

21 January 2018

Immunological tolerance.

1 reference

12 December 2020

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

1 reference

12 December 2020

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF

1 reference

12 December 2020

Neutralizing antibodies to multiple sclerosis treatments.

1 reference

12 December 2020

Enzymatic Defect in Fabry's Disease

1 reference

12 December 2020

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C

1 reference

12 December 2020

Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme

1 reference

12 December 2020

Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy

1 reference

12 December 2020

Post-translational modifications of proteins: acetylcholinesterase as a model system

1 reference

12 December 2020

Is globotriaosylceramide a useful biomarker in Fabry disease?

1 reference

12 December 2020

Fabry disease in patients with end-stage renal failure: the potential benefits of screening

1 reference

12 December 2020

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta

1 reference

12 December 2020

Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria

1 reference

12 December 2020

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

1 reference

12 December 2020

Human alpha-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells

1 reference

12 December 2020

Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase

1 reference

12 December 2020

Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease

1 reference

12 December 2020

Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.

1 reference

12 December 2020

Immunogenicity of recombinant human proteins: causes and consequences

1 reference

12 December 2020

Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice

1 reference

12 December 2020

The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative

1 reference

12 December 2020

Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration

1 reference

12 December 2020

Immunogenicity of recombinant DNA human insulin

1 reference

12 December 2020

Perspectives from B cell immunology: fact and fancy.

1 reference

12 December 2020

Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease

1 reference

12 December 2020

Antibodies to recombinant human erythropoietin causing pure red cell aplasia

1 reference

12 December 2020

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

12 December 2020

Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells

1 reference

12 December 2020

Human antibodies to insulin in diabetes

1 reference

12 December 2020

The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease

1 reference

12 December 2020

10.1007/S10545-011-9400-Y

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22037707